Omni Shrimp (OMSH) 10-Q20 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
Document And Entity Information	Mar. 31, 2014	15-May-14
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'NNAN	'
Entity Common Stock, Shares Outstanding	'	597,473,866
Entity Registrant Name	'NaturalNano, Inc.	'
Entity Central Index Key	'0000863895	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$7,753	$0
Accounts Receivable	12,250	23,206
Inventory	18,725	13,246
Prepaid expenses and other current assets	7,040	7,040
Receivable due from MJ Enterprises	200,000	0
Total current assets	245,768	43,492
Total Assets	245,768	43,492
Current liabilities:	'	'
Notes Payable (See Note 2)	4,408,435	4,088,425
Accounts payable	414,510	448,127
Accrued expenses	94,752	100,331
Accrued interest	706,807	611,261
Accrued payroll	1,000,784	978,340
Deferred revenue	70,745	30,000
Registration rights liability (See Note 2)	82,489	82,489
Derivative liability (see Note 4)	58,727	32,419
Total current liabilities	6,837,249	6,371,392
Total Liabilities	6,837,249	6,371,392
Commitments and contingencies (See Note 7)	'	'
Stockholders' Deficiency	'	'
Common Stock - $.001 par value 800,000,000 authorized with 597,473,866 and 554,339,146 issued and outstanding, respectively	597,474	554,339
Additional paid in capital	21,248,433	21,176,747
Accumulated deficit	-28,565,931	-28,302,351
Total stockholders' deficiency	-6,720,024	-6,571,265
Total liabilities and stockholders' deficiency	245,768	43,492
Series B Preferred Stock [Member]	'	'
Current liabilities:	'	'
Preferred Stock - $.001 par value, 10 million shares authorized	248	425
Series C Preferred Stock [Member]	'	'
Current liabilities:	'	'
Preferred Stock - $.001 par value, 10 million shares authorized	128,295	242,940
Series D Preferred Stock [Member]	'	'
Current liabilities:	'	'
Preferred Stock - $.001 par value, 10 million shares authorized	$0	$0

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Mar. 31, 2014	Dec. 31, 2013
Preferred Stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	800,000,000	800,000,000
Common Stock, shares issued	597,473,866	554,339,146
Common Stock, shares outstanding	597,473,866	554,339,146
Series B Preferred Stock [Member]	'	'
Preferred Stock, aggregate liquidation preference	$10	$10
Preferred Stock, shares issued	5,000	5,000
Preferred Stock, shares outstanding	5,000	5,000
Series C Preferred Stock [Member]	'	'
Preferred Stock, aggregate liquidation preference	$5,175	$5,715
Preferred Stock, shares issued	2,587,674	2,857,266
Preferred Stock, shares outstanding	2,587,674	2,857,266
Series D Preferred Stock [Member]	'	'
Preferred Stock, shares issued	100	100
Preferred Stock, shares outstanding	100	100

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Mar. 31, 2014	Mar. 31, 2013
Income:	'	'
Revenue	$3,640	$5,898
Cost of goods sold	485	451
Gross profit	3,155	5,447
Operating expenses:	'	'
Research and development	10,735	14,930
General and administrative	94,145	70,301
Total operating expenses	104,880	85,231
Loss from Operations	-101,725	-79,784
Other expense:	'	'
Interest expense, net	-95,547	-90,122
Net loss on derivative liability	-26,308	-9,834
Loss on modification of debt	-40,000	-30,000
Other expense	-161,855	-129,956
Net loss from continuing operations	-263,580	-209,740
Net income from discontinued operations	0	9,093
Consolidated net loss	($263,580)	($200,647)
Continuing operations loss per common share - basic and diluted (in dollars per share)	$0	$0
Discontinued operations income per common share- basic and diluted (in dollars per share)	$0	$0
Weighted average shares outstanding (in shares)	581,178,527	142,840,123

CONSOLIDATED_STATEMENT_OF_STOC

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY DEFICIENCY (USD $)	Total	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance at Dec. 31, 2013	($6,571,265)	$554,339	$0	$21,176,747	($28,302,351)
Balance (in shares) at Dec. 31, 2013	'	554,339,146	100	'	'
Series C preferred shares converted to common stock and change in value	114,821	43,135	0	71,686	0
Series C preferred shares converted to common stock and change in value (in shares)	'	43,134,720	0	'	'
Net loss for the three months ended March 31, 2014	-263,580	0	0	0	-263,580
Balance at Mar. 31, 2014	($6,720,024)	$597,474	$0	$21,248,433	($28,565,931)
Balance (in shares) at Mar. 31, 2014	'	597,473,866	100	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities:	'	'
Consolidated net loss	($263,580)	($200,647)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Fair value adjustment of derivative liabilities	26,308	9,834
Issuance of warrants for services	0	3,077
Loss on modification of debt	40,000	30,000
Changes in operating assets and liabilities:	'	'
Increase in inventory	-5,479	-60
Decrease (increase) in accounts receivable	10,956	-15,500
Decrease in other current assets	0	1,173
Increase in accounts payable, accrued payroll and accrued expenses	78,803	115,141
Increase in deferred revenue	40,745	0
Net cash used in operating activities	-72,247	-56,982
Cash flows from investing activities:	'	'
Receivable due from MJ Enterprises	-200,000	0
Net cash used in investing activities	-200,000	0
Cash flows from financing activities:	'	'
Proceeds from senior secured Promissory Notes	280,000	56,005
Net cash provided by financing activities	280,000	56,005
Increase (decrease) in cash and cash equivalents	7,753	-977
Cash at beginning of period	0	6,160
Cash at end of period	7,753	5,183
Schedule of non-cash investing and financing activities:	'	'
Common stock issued for Convertible notes	0	10,013
Common stock issued for accrued interest	$0	$17,325

PRINCIPAL_BUSINESS_ACTIVITY_AN

PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	'
		1	PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES

	Interim Financial Statements
	The consolidated financial statements as of March 31, 2014 and for the three months ended March 31, 2014 and 2013 are unaudited. However, in the opinion of management of the Company, these financial statements reflect all material adjustments, consisting solely of normal recurring adjustments, necessary to present fairly the financial position and results of operations for such interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results to be obtained for a full year. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X for smaller reporting companies. Accordingly, these financial statements do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

	Liquidity and Going Concern
	Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred a net loss for the three months ended March 31, 2014 of approximately $264,000 and had negative working capital of approximately $6,591,000 and a stockholders’ deficiency of $6,720,024 at March 31, 2014. Since inception the Company’s growth has been funded through a combination of convertible and non-convertible debt from private investors and from cash advances from its former parent Technology Innovations, LLC. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, renegotiate the terms of existing financing obligations and ultimately to attain successful operations. The ability to successfully achieve those items is uncertain. The financial statements do not include any adjustments that might result from the uncertainty.

	As of March 31, 2014, the Company continued to require waivers for debt covenant violations and extensions of maturity dates. Refer to Note 2 for lenders waivers and maturity extensions received from the lenders.

	Basis of Consolidation
	The consolidated financial statements include the accounts of NaturalNano, Inc. (“NaturalNano” or the “Company”), a Nevada corporation, and its wholly owned subsidiary NaturalNano Research, Inc. (“NN Research”) a Delaware corporation. All significant inter-company accounts and transactions have been eliminated in consolidation.

	Description of the Business
	NaturalNano (the “Company”), located in Rochester, New York, is engaged in the development and commercialization of material science technologies with an emphasis on additives to polymers and other industrial and consumer products by taking advantage of technology advances developed in-house. The Company’s current activities are directed toward research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for:

		•	cosmetics, health and beauty products
		•	polymers, plastics and composites

	Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate such estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations. For stock based derivative financial instruments, the Company estimated the total enterprise value based upon trending the firm value from December 2006 to March 2014 considering company specific factors including the changes in forward estimated revenues and market factors. Once the enterprise value was determined an option pricing model was used to allocate the enterprise value to the individual derivative securities in the Company’s capital structure. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation.

	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740 which requires the recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income items is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. The Company recognizes penalties and accrued interest related to unrecognized tax benefits in income tax expense. Income tax expense was $0 for the three month periods ending March 31, 2014 and 2013.

	Loss Per Share
	Basic loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share gives effect to dilutive convertible preferred stock, convertible debt, options and warrants outstanding during the period. Shares to be issued upon the exercise of these instruments have not been included in the computation of diluted loss per share as their effect is anti-dilutive based on the net loss incurred.

	As of March 31, 2014 and 2013 there were 2,016,101,890 and 4,394,378,211 shares, respectively, underlying preferred stock, convertible debt, outstanding options and warrants that could potentially dilute future earnings. These potentially dilutive shares have been limited by certain debt and equity agreements with Platinum, Platinum Advisors, Alpha Capital and Technology Innovations LLC. These agreements provide limitations on the conversion of the dilutive instruments such that the number of shares of Common Stock that may be acquired by the holder upon conversion of such instruments shall be limited to ensure that following such conversion the total number of shares of Common Stock then beneficially owned by the holder does not exceed 4.99% of the total number of issued and outstanding shares of Common Stock. The Company does not have sufficient authorized shares to satisfy conversion of all the potentially dilutive instruments.

	Recent Accounting Pronouncements

	Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted, would have a material effect on the accompanying financial statements.

NOTES_PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	2	NOTES PAYABLE

	Notes payable consisted of the following:

	Notes Payable		March 31,		December 31,
			2014		2013
	Senior Secured Convertible Notes		$	3,124,403	$	3,124,403
	Senior Secured Promissory Notes			972,932		692,922
	Subordinated Secured Convertible Note			311,100		271,100
			$	4,408,435	$	4,088,425
	Senior Secured Convertible Notes and Senior Secured Promissory Notes
	As of March 31, 2014, Notes payable on the balance sheet includes $4,097,335 ($3,817,325 at December 31, 2013) for senior secured convertible and non-convertible promissory notes. As further described below, the Company has defaulted on certain provisions of the notes. Platinum Long Term Growth and Merit Consulting, LLC (to whom Platinum Advisors has assigned their ownership interest in notes receivable from the Company) have granted waivers of default on their outstanding principal balance through June 30, 2014. Alpha Capital Anstalt (to whom Longview Special Finance has assigned its ownership interest in notes receivable to the Company) has granted a waiver of default on their outstanding principal through June 30, 2014.

	The Loan and Security Agreement and the related underlying convertible notes issued in accordance with the Initial Note agreement had the original conversion price of $3.74 (as cited in the March 7, 2007 agreement) which was adjusted to a conversion price of $0.085 in accordance with the anti-dilution provisions of this loan and security agreement. This conversion price adjustment was triggered as a result of the issuance of the 2008 Promissory Notes (described below) on September 29, 2008 thereby resulting in a reset of (a) the conversion price of the Initial Notes, (b) the exercise price of the warrants related to the Initial Notes and (c) the number of shares that may be purchased by such warrants. As compensation for forbearance from the lenders in 2012, the conversion rate was further adjusted to 75% of the lowest VWAP for the 1, 5 or 10 days immediately prior to the conversion.

	During the three month period ended March 31, 2013, the Company issued 9,500,000 shares of common stock to Alpha Capital Anstalt upon the conversion of $10,013 of outstanding principal due on the 8% Senior Secured Convertible Notes held by Longview Special Finance. Also during this period the Company issued 9,500,000 shares of common stock to Alpha Capital Anstalt upon the conversion of $8,550 of interest due on the 8% Senior Secured Convertible Notes held by Longview Special Finance.

	2014 Senior Secured Promissory Notes
	During the first quarter of 2014, the Company entered into various Senior Secured Promissory Notes aggregating to $280,000 with Platinum, Longview and Alpha (“the 2014 Senior Secured Promissory Notes”). The 2014 Senior Secured Promissory Notes are secured by, among other things, (i) the continuing security interest in certain assets of the Company pursuant to the terms of the Initial Notes dated March 7, 2007, (ii) the Pledge Agreement, as defined in the Initial Notes, and (iii) the Patent Security Agreement, dated as of March 6, 2007. The proceeds from the 2014 Senior Secured Promissory Notes are available for general working capital purposes and cannot be used to redeem or make any payment on account of any securities due to the Lenders. The 2014 Senior Secured Promissory Notes bear interest, in arrears, at a rate of 8% per annum and are payable in cash as follows: $80,000 due on June 30, 2014, and $200,000 due on February 7, 2014. The $200,000 note has been extended through a forbearance agreement and is now due and payable on June 30, 2014.

	Subordinated Secured Convertible Note

	Convertible Notes
	On December 4, 2009, the Company received net proceeds of $197,500 pursuant to the terms of a subscription agreement dated as of November 30, 2009 with Cape One an accredited investor. Pursuant to the terms of the Subscription Agreement the Company issued (i) a 10% Subordinated Secured Convertible Promissory Note (“the 10% Convertible Note”) in the principal amount of $225,000 and (ii) a five-year common stock purchase warrant to purchase 2,647,059 shares, subject to certain anti-dilution provisions in the agreement of the Company’s common stock, par value $0.001 per share at an exercise price of $0.425 per share. The balance of this note as of March 31, 2014 is $311,100, a net result of increases as consideration for forbearance and conversions of principal.

	The 10% Convertible Note had a 15-month term, bears interest at 10% per annum and is secured by certain assets of the Company pursuant to a security agreement, dated November 30, 2009. The 10% Convertible Note is convertible into Common Stock at any time prior to maturity (provided that such conversion does not result in the holder and its affiliates beneficially owning in excess of 4.99% (9.99% upon 61 days’ prior written notice) of the issued and outstanding Common Stock at $0.085 per share (the “Conversion Price”), subject to adjustment upon the occurrence of certain anti-dilution events. Interest under the Note is due quarterly in cash or if registered, in the Company’s common stock at a 20% discount in accordance with a formula set forth in the 10% Note. The 10% Note and security interest is subordinate to certain outstanding senior indebtedness of the Company held by Platinum Long Term Growth IV, LLC, Platinum Advisors LLC and Longview Special Finance Inc. (“Senior Lenders”). Upon the occurrence of Events of Default as set forth in the Note, the principal and interest due under the Note may be accelerated and the interest rate payable may be increased to 18%. The company has entered into various forbearance agreements between Cape One and the Company which extended the due date of the outstanding principal and interest.

	During the three month periods ended March 31, 2014 and March 31, 2013, the Company entered into forbearance agreements with Cape One which extended the due dates of certain outstanding notes and accrued interest. As consideration for this forbearance, the lender increased its principal balance outstanding by $40,000 and $30,000 in the respectively periods cited above. These amounts were added to the principal balance of the Initial Notes and the Company recognized a loss on modification of debt of $40,000 and $30,000, respectively in the three month periods ended March 31, 2014 and March 31, 2013. This note has been extended through forbearance agreements and is now due and payable on May 30, 2014.

	During three month period ended March 31, 2013, the Company issued 9,000,000 shares of common stock to Cape One in payment of $8,775 of interest expense obligations on the Subordinated Secured Convertible Note.

	Registration Rights Agreement
	On March 7, 2007, the Company entered into a Registration Rights Agreement with the Agent and the other investors, pursuant to which the Company agreed to prepare and file within 60 days of the March 7, 2007 agreement, a registration statement for resale under the Securities Act of 1933, the common stock issuable upon the exercise of the Warrants, in payment of interest on, or upon conversion of, the Notes. The Company further agreed to use its best efforts to cause the Registration Statement to be declared effective 120 days following the March 7, 2007 agreement date, or within 150 days if the Company receives a comment letter from the SEC, and to maintain such Registration Statement for the two year period following this date. This agreement allows for liquidated damages based on a daily amount of 0.0333% of the principal amount of the notes relating to the common stock issuable upon conversion of the Notes included in the Registration Statement.

	As of March 31, 2014, the registration statement had not been updated with the requisite SEC filings and as such, the Company was in default of this provision of the Registration Rights Agreement. The lenders have provided the Company forbearance agreements related to this default through June 30, 2014. The Company recorded a total of $146,028 in such liquidated damages as of December 17, 2007, the date the registration statement was declared effective. As of December 31, 2007, $63,539 of this obligation was paid in cash and $82,489 was recorded as an accrued liability. The lender has the option to settle the liquidated damages in common stock valued at the average price for the five days prior to the end of a payment period. At March 31, 2014 and December 31, 2013 the outstanding balance for this obligation was $82,489.

DERIVATIVE_LIABILITY

DERIVATIVE LIABILITY	3 Months Ended
DERIVATIVE LIABILITY	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivative Instruments and Hedging Activities Disclosure [Text Block]	'
	3	DERIVATIVE LIABILITY

	For stock based derivative financial instruments, the Company estimated the total enterprise value based upon trending of the firm value from December 2006 to December 2013 considering company specific factors including the changes in forward estimated revenues and market factors. Once the enterprise value was determined an option pricing model was used to allocate the enterprise value to the individual derivative and other securities in the Company’s capital structure. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

	The Company’s derivative liabilities as of March 31, 2014 are as follows:

		·	The debt conversion feature embedded in the 8% Senior Secured Convertible notes entered into in March 2007 which contains anti-dilution provisions that would be triggered if the Company issued instruments with rights to the Company’s common stock at prices below this exercise price (described in Note 2.)
		·	The debt conversion feature and the 2,647,059 warrants exercisable at $0.425 per share granted in connection with the 10% Subordinated Secured Convertible debt entered into in November 2009. These agreements contain anti-dilution provisions that would be triggered if the Company issued instruments with rights to the Company’s common stock at prices below the exercise price (described in Note 2.)
		·	Derivative liabilities related to outstanding warrants and options due to the Company having insufficient authorized shares to satisfy the exercise or conversion of all outstanding instruments as of March 31, 2014.

	The fair value of the derivative liabilities as of March 31, 2014 and December 31, 2013 are as follows:

			March 31,		December 31,
			2014		2013
	Derivative Instrument
	8% Notes conversion feature		$	44,137	$	18,045
	10% Notes conversion feature			5,920		3,946
	Warrant liability			8,670		10,428
	Total		$	58,727	$	32,419

	The increase in the fair value of the derivative liability of $26,308 was recognized as a loss on change in derivative liability in the statement of operations for the three months ended March 31, 2014.

	Significant fluctuations in the variables used in calculating the value of the Company’s derivative liabilities could have significant impact on the fair market valuation.

	Fair Value Valuation Hierarchy Measurement
	ASC 820 establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows.

		·	Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities.
		·	Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.
		·	Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to measure assets and liabilities at fair value.

	A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. The Company’s derivative liability was determined utilizing Level 3 inputs.

STOCKHOLDERS_EQUITY

STOCKHOLDERS EQUITY	3 Months Ended
	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	4	STOCKHOLDERS EQUITY

	As of March 31, 2014 the Company was authorized to issue up to 800,000,000 shares of common stock and 10,000,000 shares of preferred stock.

	Increase in Authorized Common Stock: On July 1, 2013 the Company received a unanimous written consent in lieu of a meeting from the members of the Board of Directors and a written consent from the Series D stockholder to amend its articles of incorporation to increase the Company’s authorized common shares to 800,000,000 shares of common stock. As of March 31, 2014 there were 1,974,710,583 shares underlying preferred stock, convertible debt, outstanding options and warrants that could potentially dilute future earnings. The Company does not have sufficient authorized shares to satisfy conversion of all the potentially dilutive instruments.

	Preferred Stock Issuances
	On September 29, 2008 Platinum and Longview agreed to exchange detachable warrants to purchase 71,691,180 shares of common stock of the Company for $0.085 per share held by such Investors related to the March 6, 2007 convertible notes payable for 5,000,000 shares of preferred stock.

	On October 7, 2008, the Company filed a Certificate of Designation of Rights, Preferences, Designations, Qualifications and Limitations of the Series C Preferred Stock (the “Series C Designation”) with the Secretary of State of the State of Nevada, and prepared a preferred stock certificate for delivery to Platinum Long Term Growth IV, LLC, evidencing 4,250,000 shares of Series C Convertible Preferred Stock of the Company (“Series C”). On October 7, 2008, the Company also filed a Certificate of Designation of Rights, Preferences, Designations, Qualifications and Limitations of the Series B Preferred Stock (the “Series B Designation”) with the Secretary of State of the State of Nevada, and prepared a preferred stock certificate for delivery to Longview Special Funding, Inc., evidencing 750,000 shares of Series B Convertible Preferred Stock of the Company (“Series B”). The Series B and Series C have an aggregate liquidation preference of $10,000 and participate in any dividends or distributions to the common shareholders on an as converted basis.

	Each share of the Series B and Series C Convertible Preferred Stock is convertible into 160 shares of the Company’s common stock and votes on an as-converted basis (with each share having 160 votes). The conversion rate was reduced to 9.41 as a result of the 2012 reverse split, but was subsequently changed back to 160 as part of the consideration related to 2012 forbearance agreements. Both the Series B and Series C designations limits the holders’ rights to convert its Convertible Preferred Stock, and the aggregate voting powers, to no more than 4.99% of the votes attributable to the total outstanding common shares. Accordingly, the votes attributable to the Series B and Series C Convertible Preferred constitutes 4.99% of the aggregate votes attributable to the Company’s outstanding shares on an as converted basis and the votes Series B and Series C Convertible Preferred and the Series C Convertible Preferred, voting together represent approximately 9.98% of the aggregate votes attributable to the Company’s outstanding shares (on an as converted basis). The Series B Convertible Preferred Stock has an aggregate liquidation value of $10 and the Series C Convertible Preferred Stock has an aggregate liquidation value of $5,175.

	As a result of the Company not having sufficient authorized shares to satisfy the conversion of all outstanding convertible debt, convertible preferred stock, warrants and options, the Series B and C preferred shares have been moved into temporary equity classification on the balance sheet.

	During first quarter of 2014, Platinum elected to convert 269,592 shares of their Series C preferred shares into 43,134,720 common shares at the conversion rate of 160 common shares per each Series C share.

	During the first quarter of 2013, Alpha elected to convert 137,500 shares of Series B preferred shares owned by Longview into 22,000,000 common shares at the conversion rate of 160 common shares per each Series B share. During first quarter of 2013, Platinum elected to convert 508,022 shares of their Series C preferred shares into 81,283,520 common shares at the conversion rate of 160 common shares per each Series C share.

	Common Stock Issuances
	During the three months ended March 31, 2013, the Company issued an aggregate of 18,500,000 shares in satisfaction of $8,550 of interest obligations to Alpha Capital and $8,775 of interest obligations to Cape One. Also during this period, the Company issued an aggregate of 9,500,000 shares of its common stock in satisfaction of $10,013 of principal obligations to Alpha Capital.

	Warrants Grants
	The Company has issued warrants to purchase shares of its common stock to certain consultants and debt holders. As of March 31, 2014 and December 31, 2013 there were common stock warrants outstanding to purchase an aggregate of 118,235,294 shares of common stock pursuant to the warrant grant agreements.

	A summary of the outstanding warrants is presented below:

			2014
			Shares		Weighted		Weighted
					Average		Average
					Exercise		Remaining
					Price		Life-years

	Outstanding at January 1, 2014			118,235,294	$	0.0142		5.9
	Granted during the first quarter of 2014			-
	Cancelled or forfeited			-
	Warrants outstanding at March 31, 2014			118,235,294	$	0.0142		5.65
	Warrants exercisable at March 31, 2014			118,235,294	$	0.0142		5.65

INCENTIVE_STOCK_PLANS

INCENTIVE STOCK PLANS	3 Months Ended
INCENTIVE STOCK PLANS	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	5	INCENTIVE STOCK PLANS

	A summary of the status of the outstanding incentive stock plans is presented below at March 31, 2014:

			Shares		Weighted		Weighted Average
					Average		Remaining
					Exercise Price		Life-years

	Options outstanding at January 1, 2014			709,020	$	3.57		2.11
	Options granted/exercises/cancelled/forfeited			-
	Options outstanding at March 31, 2014			709,020	$	3.57		1.86
	Options exercisable at March 31, 2014			709,020	$	3.57		1.86

	All compensation costs for the above options have been previously recognized in operations.

DISCONTINUED_OPERATIONS

DISCONTINUED OPERATIONS	3 Months Ended
	Mar. 31, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	'
	6	DISCONTINUED OPERATIONS

	In the second quarter of 2013, the Company ceased all activities associated with the Medical Board business segment. The Company assessed this segment and determined that inadequate income had been generated relative to the efforts of production and administrative support. The Statement of Operations for the three month period ended March 31, 2013 reflects the Medical Board business as a discontinued operation. The first quarter of 2013 included revenues from this discontinued operation of $13,000, cost of goods sold of $3,907 and gross margin of $9,093. In connection with this decision to exit the Medical Board business, the Company filed a Certificate of Dissolution on May 10, 2013 with the state of New York under section 1003 of the Business Corporation Law in connection with the unanimous written consent of the shareowners of Combotexs. The Nanotechnology business remains as the Company’s only reportable operating segment.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	7	SUBSEQUENT EVENTS

	Purchase Agreement with MJ Enterprises
	On January 30, 2014, NaturalNano, Inc. entered into a purchase agreement to acquire all the issued and outstanding membership units of MJ Enterprises (“MJE”) from Jackson August Holdings, LLC, JFish, LLC and Adventure CNY LLC. MJE is in the business of developing, manufacturing, marketing, distributing and selling plating products through GSP LLC. a wholly owned subsidiary. In May 2014 the Company determined that the transaction should not proceed after due diligence was completed. MJE has committed to return proceeds advanced by NNAN which includes a loan of $200,000 collateralized with assets of the MJE and Personal Guarantees.

	8% Convertible Promissory Note- Marlin Capital Investments LLC
	On May 8, 2014, the Company entered into $45,000 convertible promissory note with Marlin Capital Investments LLC. The note is due on June 30, 2014, bears interest at 8% per annum and the note and interest accrued on the note are convertible into the Company’s common stock at any time prior to maturity (provided that such conversion does not result in the holder and its affiliates beneficially owning in excess of 4.99% of the issued and outstanding Common Stock) at $0.22 per share subject to adjustment upon the occurrence of certain anti-dilution events.

	Grant of Warrants
	On May 8, 2014, the Company granted 48 million warrants to certain employees and consultants with an exercise price of $0.0014 per share, a term of 5 years and which allow for cashless exercise. The Company’s stock price was $.0022 per share on the date the warrants were granted.

PRINCIPAL_BUSINESS_ACTIVITY_AN1

PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Interim Financial Statements [Policy Text Block]	'
	Interim Financial Statements
	The consolidated financial statements as of March 31, 2014 and for the three months ended March 31, 2014 and 2013 are unaudited. However, in the opinion of management of the Company, these financial statements reflect all material adjustments, consisting solely of normal recurring adjustments, necessary to present fairly the financial position and results of operations for such interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results to be obtained for a full year. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X for smaller reporting companies. Accordingly, these financial statements do not include all of the information required by U.S. generally accepted accounting principles for complete financial statements. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

Liquidity Disclosure [Policy Text Block]	'
	Liquidity and Going Concern
	Going Concern – The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred a net loss for the three months ended March 31, 2014 of approximately $264,000 and had negative working capital of approximately $6,591,000 and a stockholders’ deficiency of $6,720,024 at March 31, 2014. Since inception the Company’s growth has been funded through a combination of convertible and non-convertible debt from private investors and from cash advances from its former parent Technology Innovations, LLC. These factors, among others, may indicate that the Company will be unable to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations, to obtain additional financing, renegotiate the terms of existing financing obligations and ultimately to attain successful operations. The ability to successfully achieve those items is uncertain. The financial statements do not include any adjustments that might result from the uncertainty.

	As of March 31, 2014, the Company continued to require waivers for debt covenant violations and extensions of maturity dates. Refer to Note 2 for lenders waivers and maturity extensions received from the lenders.

Consolidation, Policy [Policy Text Block]	'
	Basis of Consolidation
	The consolidated financial statements include the accounts of NaturalNano, Inc. (“NaturalNano” or the “Company”), a Nevada corporation, and its wholly owned subsidiary NaturalNano Research, Inc. (“NN Research”) a Delaware corporation. All significant inter-company accounts and transactions have been eliminated in consolidation.

Business Description [Policy Text Block]	'
	Description of the Business
	NaturalNano (the “Company”), located in Rochester, New York, is engaged in the development and commercialization of material science technologies with an emphasis on additives to polymers and other industrial and consumer products by taking advantage of technology advances developed in-house. The Company’s current activities are directed toward research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for:

		•	cosmetics, health and beauty products
		•	polymers, plastics and composites

Use of Estimates, Policy [Policy Text Block]	'
	Estimates
	The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Actual results could differ materially from these estimates. On an ongoing basis, we evaluate such estimates. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities.

Derivatives, Policy [Policy Text Block]	'
	Derivative Financial Instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair market value and then is revalued at each reporting date, with changes in fair value reported in the consolidated statement of operations. For stock based derivative financial instruments, the Company estimated the total enterprise value based upon trending the firm value from December 2006 to March 2014 considering company specific factors including the changes in forward estimated revenues and market factors. Once the enterprise value was determined an option pricing model was used to allocate the enterprise value to the individual derivative securities in the Company’s capital structure. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance sheet date.

Reclassification, Policy [Policy Text Block]	'
	Reclassifications
	Certain prior year amounts have been reclassified to conform to the current year presentation.

Income Tax, Policy [Policy Text Block]	'
	Income Taxes
	The Company accounts for income taxes in accordance with ASC 740 which requires the recognition of estimated income taxes payable or refundable on income tax returns for the current year and for the estimated future tax effect attributable to temporary differences and carry-forwards. Measurement of deferred income items is based on enacted tax laws including tax rates, with the measurement of deferred income tax assets being reduced by available tax benefits not expected to be realized. The Company recognizes penalties and accrued interest related to unrecognized tax benefits in income tax expense. Income tax expense was $0 for the three month periods ending March 31, 2014 and 2013.

Earnings Per Share, Policy [Policy Text Block]	'
	Loss Per Share
	Basic loss per common share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per common share gives effect to dilutive convertible preferred stock, convertible debt, options and warrants outstanding during the period. Shares to be issued upon the exercise of these instruments have not been included in the computation of diluted loss per share as their effect is anti-dilutive based on the net loss incurred.

	As of March 31, 2014 and 2013 there were 2,016,101,890 and 4,394,378,211 shares, respectively, underlying preferred stock, convertible debt, outstanding options and warrants that could potentially dilute future earnings. These potentially dilutive shares have been limited by certain debt and equity agreements with Platinum, Platinum Advisors, Alpha Capital and Technology Innovations LLC. These agreements provide limitations on the conversion of the dilutive instruments such that the number of shares of Common Stock that may be acquired by the holder upon conversion of such instruments shall be limited to ensure that following such conversion the total number of shares of Common Stock then beneficially owned by the holder does not exceed 4.99% of the total number of issued and outstanding shares of Common Stock. The Company does not have sufficient authorized shares to satisfy conversion of all the potentially dilutive instruments.

New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements

	Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted, would have a material effect on the accompanying financial statements.

NOTES_PAYABLE_Tables

NOTES PAYABLE (Tables)	3 Months Ended
NOTES PAYABLE (Tables)	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
	Notes payable consisted of the following:

	Notes Payable	March 31,		December 31,
	Notes Payable	2014		2013
	Senior Secured Convertible Notes	$	3,124,403	$	3,124,403
	Senior Secured Promissory Notes		972,932		692,922
	Subordinated Secured Convertible Note		311,100		271,100
		$	4,408,435	$	4,088,425

DERIVATIVE_LIABILITY_Tables

DERIVATIVE LIABILITY (Tables)	3 Months Ended
DERIVATIVE LIABILITY (Tables)	Mar. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	'
	The fair value of the derivative liabilities as of March 31, 2014 and December 31, 2013 are as follows:

		March 31,		December 31,
		2014		2013
	Derivative Instrument
	8% Notes conversion feature	$	44,137	$	18,045
	10% Notes conversion feature		5,920		3,946
	Warrant liability		8,670		10,428
	Total	$	58,727	$	32,419

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS EQUITY (Tables)	3 Months Ended
STOCKHOLDERS EQUITY (Tables)	Mar. 31, 2014
Stockholders' Equity Note [Abstract]	'
Class Of Warrant Outstanding [Table Text Block]	'
	A summary of the outstanding warrants is presented below:

		2014
		Shares		Weighted		Weighted
				Average		Average
				Exercise		Remaining
				Price		Life-years

	Outstanding at January 1, 2014		118,235,294	$	0.0142		5.9
	Granted during the first quarter of 2014		-
	Cancelled or forfeited		-
	Warrants outstanding at March 31, 2014		118,235,294	$	0.0142		5.65
	Warrants exercisable at March 31, 2014		118,235,294	$	0.0142		5.65

INCENTIVE_STOCK_PLANS_Tables

INCENTIVE STOCK PLANS (Tables)	3 Months Ended
INCENTIVE STOCK PLANS (Tables)	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	A summary of the status of the outstanding incentive stock plans is presented below at March 31, 2014:

		Shares		Weighted		Weighted Average
				Average		Remaining
				Exercise Price		Life-years

	Options outstanding at January 1, 2014		709,020	$	3.57		2.11
	Options granted/exercises/cancelled/forfeited		-
	Options outstanding at March 31, 2014		709,020	$	3.57		1.86
	Options exercisable at March 31, 2014		709,020	$	3.57		1.86

PRINCIPAL_BUSINESS_ACTIVITY_AN2

PRINCIPAL BUSINESS ACTIVITY AND SIGNIFICANT ACCOUNTING POLICIES (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Accounting Policies [Line Items]	'	'	'
Net loss attributable to controlling interest	($263,580)	($200,647)	'
Working Capital Deficit	6,591,000	'	'
Total stockholders' deficiency	-6,720,024	'	-6,571,265
Weighted Average Number of Shares Outstanding, Diluted	2,016,101,890	4,394,378,211	'
Stock Conversion Limit Percentage	4.99%	'	'
Income Tax Expense (Benefit)	$0	$0	'

NOTES_PAYABLE_Details

NOTES PAYABLE (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Notes Payable [Line Items]	'	'
Notes payable, Total	$4,408,435	$4,088,425
Senior Secured Convertible Notes [Member]	'	'
Notes Payable [Line Items]	'	'
Notes payable, Total	3,124,403	3,124,403
Senior Secured Promissory Note [Member]	'	'
Notes Payable [Line Items]	'	'
Notes payable, Total	972,932	692,922
Subordinated Secured Convertible Notes [Member]	'	'
Notes Payable [Line Items]	'	'
Notes payable, Total	$311,100	$271,100

NOTES_PAYABLE_Details_Textual

NOTES PAYABLE (Details Textual) (USD $)

0 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

0 Months Ended

3 Months Ended

Mar. 07, 2007

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2007

Dec. 31, 2013

Nov. 30, 2009

Dec. 17, 2007

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

Dec. 04, 2009

Nov. 30, 2009

Mar. 31, 2014

Nov. 30, 2009

Feb. 07, 2014

Mar. 31, 2014

Five Year Common Stock Purchase Warrant [Member]

Cape One [Member]

Senior Secured Convertible Promissory Notes [Member]

8% Senior Secured Convertible Notes [Member]

10% Subordinated Secured Convertible Promissory Note [Member]

Convertible Note Covenants and Other Agreements [Member]

Senior Convertible Promissory Notes 2014 [Member]

Notes Payable [Line Items]

Notes Payable, Total

$4,408,435

$4,088,425

$4,097,335

$3,817,325

Debt Instrument Convertible Conversion Price Initial

$3.74

Debt Instrument, Convertible, Conversion Price

$0.09

Debt Instrument, Convertible, Terms of Conversion Feature

'As compensation for forbearance from the lenders in 2012, the conversion rate was further adjusted to 75% of the lowest VWAP for the 1, 5 or 10 days immediately prior to the conversion.

'The 10% Convertible Note is convertible into Common Stock at any time prior to maturity (provided that such conversion does not result in the holder and its affiliates beneficially owning in excess of 4.99% (9.99% upon 61 days prior written notice) of the issued and outstanding Common Stock at $0.085 per share (the Conversion Price), subject to adjustment upon the occurrence of certain anti-dilution events.

Debt Instrument Convertible Number Of Equity Instruments For Outstanding Principal

9,500,000

9,000,000

9,500,000

Convertible Debt

8,550

10,013

Debt Instrument Convertible Number Of Equity Instruments For Accrued Interest

8,775

Notes Payable Interest Payment

200,000

80,000

Forbearance Charges Added To Principal Balance

311,100

200,000

Loss On Modification Notes Payable

40,000

30,000

Proceeds from Issuance of Secured Debt

197,500

Notes Issued

225,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights

2,647,059

Class Of Warrant Or Right Par Value Of Securities Called By Warrants Or Rights

$0.00

Class of Warrant or Right, Exercise Price of Warrants or Rights

0.425

Interest Payment Percentage Payable On Default

18.00%

Accrued Registration Rights Obligation

82,489

Debt Instrument, Interest Rate, Stated Percentage

8.00%

10.00%

Debt Instrument For Bearance Interest Rate Percentage

8.00%

Stock Issued During Period, Shares, New Issues

280,000

Debt Instrument, Term

'15 months

Liquidated Damage Allowed As Percentage Of Note

0.03%

Liquidated Damages

146,028

Liquidated Damages Paid Value

63,539

Debt Instrument For Bearance Increased Amount

$40,000

$30,000

DERIVATIVE_LIABILITIES_Details

DERIVATIVE LIABILITIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Derivative [Line Items]	'	'
Derivative Liability, Fair Value, Net	$58,727	$32,419
Warrant liability [Member]	'	'
Derivative [Line Items]	'	'
Derivative Liability, Fair Value, Net	8,670	10,428
8% Notes conversion feature [Member]	'	'
Derivative [Line Items]	'	'
Derivative Liability, Fair Value, Net	44,137	18,045
10% Notes conversion feature [Member]	'	'
Derivative [Line Items]	'	'
Derivative Liability, Fair Value, Net	$5,920	$3,946

DERIVATIVE_LIABILITIES_Details1

DERIVATIVE LIABILITIES (Details Textual) (USD $)	3 Months Ended
DERIVATIVE LIABILITIES (Details Textual) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013	Nov. 30, 2009
Derivative [Line Items]	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	'	'	10.00%
Class of Warrant or Right, Outstanding	118,235,294	'	118,235,294	2,647,059
Class of Warrant or Right, Exercise Price of Warrants or Rights	'	'	'	0.425
Unrealized Gain (Loss) On Derivatives	($26,308)	($9,834)	'	'

STOCKHOLDERS_EQUITY_Details

STOCKHOLDERS EQUITY (Details) (Warrant [Member], USD $)	3 Months Ended
STOCKHOLDERS EQUITY (Details) (Warrant [Member], USD $)	Mar. 31, 2014
Warrant [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Shares Outstanding at beginning of year	118,235,294
Shares Granted during the year	0
Shares Cancelled or forfeited	0
Shares outstanding at end of year	118,235,294
Shares exercisable at end of year	118,235,294
Weighted Average Exercise Price Outstanding at beginning of year	$0.01
Weighted Average Exercise Price outstanding at end of year	$0.01
Weighted Average Exercise Price exercisable at end of year	$0.01
Weighted Average Remaining Life-years Outstanding at beginning of year	'5 years 10 months 24 days
Weighted Average Remaining Life years Warrants outstanding at end of year	'5 years 7 months 24 days
Weighted Average Remaining Life years Warrants exercisable at end of year	'5 years 7 months 24 days

STOCKHOLDERS_EQUITY_Details_Te

STOCKHOLDERS EQUITY (Details Textual) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Jul. 01, 2013

Nov. 30, 2009

Mar. 31, 2014

Mar. 31, 2013

Oct. 07, 2008

Mar. 31, 2014

Dec. 31, 2013

Oct. 07, 2008

Mar. 31, 2014

Dec. 31, 2013

Oct. 07, 2008

Mar. 31, 2014

Mar. 31, 2013

Sep. 29, 2008

Convertible Preferred Stock [Member]

Series B Preferred Stock [Member]

Series B and Series C Convertible Preferred Stock [Member]

Series C Preferred Stock [Member]

Platinum Partners Long Term Growth IV [Member]

Alpha Capital [Member]

Longview Special Financing Inc [Member]

Cape One [Member]

Platinum Partners Long Term Growth Iv and Longview Special Financing Inc [Member]

Llc Series C Convertible Preferred Stock [Member]

Series C Preferred Stock [Member]

Series B Preferred Stock [Member]

Schedule of Equity Method Investments [Line Items]

Debt Instrument, Convertible, Conversion Price

$9.41

Stock Issued During Period, Shares, Conversion Of Convertible Securities

43,134,720

81,283,520

9,500,000

22,000,000

Stock Issued During Period, Value, Issued for Services

$269,592

$508,022

Conversion of Stock, Shares Converted

137,500

Conversion of Stock, Shares Issued

5,000,000

Debt Conversion, Converted Instrument, Shares Issued

71,691,180

Debt Conversion, Converted Instrument, Amount

10,013

Common Stock, shares authorized

800,000,000

Preferred Stock, shares authorized

10,000,000

Common Stock, par value (in dollars per share)

$0.00

$0.09

Stock Issued During Period, Shares, Conversion of Units

750,000

160

4,250,000

160

Preferred Stock, aggregate liquidation preference

10,000

5,175

5,715

Excess Of Debt Instrument Conversion Percentage

4.99%

9.98%

Stock Issued During Period, Shares, Settlement Of Interest Obligations

18,500,000

Stock Issued During Period, Value, Settlement Of Interest Obligations

8,550

Class of Warrant or Right, Outstanding

118,235,294

2,647,059

Potential Equity Shares Outstanding

1,974,710,583

Interest Expense, Debt

$8,775

INCENTIVE_STOCK_PLANS_Details

INCENTIVE STOCK PLANS (Details) (Incentive Stock Plans [Member], USD $)	3 Months Ended
	Mar. 31, 2014
Incentive Stock Plans [Member]	'
Stock Option Plan [Line Items]	'
Shares Outstanding at beginning of year	709,020
Shares Granted/Exercises/Cancelled/Forfeited	0
Shares outstanding at end of year	709,020
Shares exercisable at end of year	709,020
Weighted Average Exercise Price Outstanding at beginning of year	$3.57
Weighted Average Exercise Price outstanding at end of year	$3.57
Weighted Average Exercise Price exercisable at end of year	$3.57
Weighted Average Remaining Life-years Outstanding at beginning of year	'2 years 1 month 10 days
Weighted Average Remaining Life years Warrants outstanding at end of year	'1 year 10 months 10 days
Weighted Average Remaining Life years Warrants exercisable at end of year	'1 year 10 months 10 days

DISCONTINUED_OPERATIONS_Detail

DISCONTINUED OPERATIONS (Details Textual) (USD $)	3 Months Ended
DISCONTINUED OPERATIONS (Details Textual) (USD $)	Mar. 31, 2013
Discontinued Operations [Line Items]	'
Gain (Loss) on Disposition of Real Estate, Discontinued Operations	$13,000
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	3,907
Disposal Group, Including Discontinued Operation, Gross Profit (Loss)	$9,093

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	Mar. 31, 2013	8-May-14	Jan. 30, 2014
Share data in Millions, except Per Share data, unless otherwise specified		Subsequent Event [Member]	Subsequent Event [Member]
			MJ Enterprises [Member]
Subsequent Event [Line Items]	'	'	'
Debt Instrument, Face Amount	'	'	$200,000
Convertible Debt	$8,550	$45,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	48	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	'	$0.00	'
Sale of Stock, Price Per Share	'	$0.00	'
Debt Instrument, Convertible, Terms Of Conversion Feature	'	'The note is due on June 30, 2014, bears interest at 8% per annum and the note and interest accrued on the note are convertible into the Companys common stock at any time prior to maturity (provided that such conversion does not result in the holder and its affiliates beneficially owning in excess of 4.99% of the issued and outstanding Common Stock) at $0.22 per share subject to adjustment upon the occurrence of certain anti-dilution events.	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	'	'5 years	'